Concepts (82)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 13 | 2023 | 4946 | 0.580 |
Why?
|
| Anti-HIV Agents | 7 | 2023 | 1275 | 0.520 |
Why?
|
| Anti-Retroviral Agents | 4 | 2023 | 542 | 0.420 |
Why?
|
| HIV-1 | 4 | 2023 | 1239 | 0.390 |
Why?
|
| Viral Load | 5 | 2023 | 808 | 0.270 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2023 | 654 | 0.250 |
Why?
|
| Child | 9 | 2023 | 2180 | 0.240 |
Why?
|
| Lamivudine | 2 | 2023 | 86 | 0.190 |
Why?
|
| Infant | 7 | 2023 | 2145 | 0.190 |
Why?
|
| Disease Management | 2 | 2019 | 73 | 0.190 |
Why?
|
| Africa, Southern | 4 | 2023 | 89 | 0.180 |
Why?
|
| Humans | 14 | 2023 | 14077 | 0.180 |
Why?
|
| Pneumonia | 1 | 2021 | 127 | 0.170 |
Why?
|
| Benzoxazines | 1 | 2020 | 119 | 0.170 |
Why?
|
| Male | 9 | 2022 | 6489 | 0.170 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2021 | 194 | 0.170 |
Why?
|
| Female | 10 | 2022 | 8751 | 0.160 |
Why?
|
| Coinfection | 1 | 2021 | 268 | 0.160 |
Why?
|
| Child, Preschool | 6 | 2021 | 1675 | 0.160 |
Why?
|
| Drug Substitution | 1 | 2019 | 29 | 0.160 |
Why?
|
| Genes, Viral | 1 | 2017 | 11 | 0.150 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 33 | 0.140 |
Why?
|
| Drug Resistance, Viral | 2 | 2017 | 268 | 0.140 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2017 | 59 | 0.140 |
Why?
|
| Point-of-Care Testing | 1 | 2017 | 68 | 0.140 |
Why?
|
| Immunogenicity, Vaccine | 1 | 2017 | 91 | 0.140 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2020 | 467 | 0.130 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 468 | 0.130 |
Why?
|
| Adolescent | 5 | 2022 | 2858 | 0.130 |
Why?
|
| South Africa | 7 | 2023 | 7312 | 0.130 |
Why?
|
| Sulfonamides | 1 | 2015 | 10 | 0.120 |
Why?
|
| HIV | 1 | 2017 | 380 | 0.120 |
Why?
|
| Streptococcus pneumoniae | 1 | 2017 | 320 | 0.120 |
Why?
|
| Pneumococcal Vaccines | 1 | 2017 | 252 | 0.120 |
Why?
|
| Ritonavir | 1 | 2015 | 137 | 0.120 |
Why?
|
| Pneumococcal Infections | 1 | 2017 | 287 | 0.110 |
Why?
|
| Risk Factors | 3 | 2022 | 1431 | 0.100 |
Why?
|
| Lost to Follow-Up | 1 | 2013 | 62 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2023 | 1410 | 0.100 |
Why?
|
| Treatment Failure | 2 | 2020 | 175 | 0.080 |
Why?
|
| Prospective Studies | 3 | 2019 | 1131 | 0.080 |
Why?
|
| Retrospective Studies | 2 | 2022 | 767 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2020 | 939 | 0.070 |
Why?
|
| Adult | 3 | 2021 | 5664 | 0.060 |
Why?
|
| Pregnancy | 2 | 2022 | 1815 | 0.060 |
Why?
|
| Dideoxynucleosides | 1 | 2023 | 29 | 0.050 |
Why?
|
| Zidovudine | 1 | 2023 | 59 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 18 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2021 | 77 | 0.050 |
Why?
|
| Child Health | 1 | 2021 | 76 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2022 | 367 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 252 | 0.040 |
Why?
|
| Serologic Tests | 1 | 2020 | 26 | 0.040 |
Why?
|
| Alkynes | 1 | 2020 | 113 | 0.040 |
Why?
|
| Cyclopropanes | 1 | 2020 | 119 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 464 | 0.040 |
Why?
|
| Prevalence | 1 | 2023 | 1149 | 0.040 |
Why?
|
| Hospitalization | 1 | 2021 | 392 | 0.040 |
Why?
|
| Developing Countries | 1 | 2021 | 385 | 0.040 |
Why?
|
| Long-Term Care | 1 | 2017 | 13 | 0.040 |
Why?
|
| Hospitals, University | 1 | 2017 | 16 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2017 | 21 | 0.040 |
Why?
|
| Lung Diseases | 1 | 2017 | 29 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2017 | 55 | 0.040 |
Why?
|
| Immunity, Humoral | 1 | 2017 | 42 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2017 | 38 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2017 | 62 | 0.030 |
Why?
|
| Serogroup | 1 | 2017 | 134 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2017 | 137 | 0.030 |
Why?
|
| Mutation | 1 | 2017 | 299 | 0.030 |
Why?
|
| Antibodies, Bacterial | 1 | 2017 | 149 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 380 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2017 | 220 | 0.030 |
Why?
|
| Darunavir | 1 | 2015 | 12 | 0.030 |
Why?
|
| Aged | 1 | 2020 | 1650 | 0.030 |
Why?
|
| HIV Protease Inhibitors | 1 | 2015 | 92 | 0.030 |
Why?
|
| Thinness | 1 | 2013 | 18 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 163 | 0.030 |
Why?
|
| Middle Aged | 1 | 2020 | 3425 | 0.030 |
Why?
|
| Caregivers | 1 | 2013 | 66 | 0.030 |
Why?
|
| Age Factors | 1 | 2013 | 364 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 503 | 0.020 |
Why?
|